tweetindex
EN

AstraZenecaUS

@AstraZenecaUS · Wilmington, DE · joined 07 Jan 2009

We're transforming the future of healthcare by unlocking the power of what science can do. Intended for US HCPs. For info visit https://t.co/1B0LbPwpeO

80 608Followers
1 769Following
8 941Posts total
10.1KViews on collected posts

Latest posts

Today, we announced positive high-level results from our latest Phase III CROSSING trial in people living with eosinophilic esophagitis (EoE), a chronic epithelial-driven inflammatory disease of the esophagus. Read more about the results: https://t.co/N8bIR9J7Qu https://t.co/UKLh
0:28
1.1K views · 6 likes · 1 reposts · 0 replies Open on X →
We rang the opening bell in a historic moment today at the @NYSE.  With #AZN trading on the #NYSE, we’re deepening our roots in the US and expanding our access to capital – fueling continued investment in the science behind a healthier America. https://t.co/QMHtrxMVD3
3.4K views · 10 likes · 1 reposts · 0 replies Open on X →
By deepening the collaboration between the UK and the US, we are accelerating scientific discovery and engaging with governments to deliver the next generation of medicines for patients worldwide. https://t.co/MjwWa3yZje
541 views · 2 likes · 0 reposts · 0 replies Open on X →
The visit was a fantastic opportunity to showcase the boundary-pushing science taking place at The DISC, our role in the Cambridge and UK life sciences ecosystem and our deep commitment to the United States. https://t.co/YPBbYDpUU0
1.2K views · 2 likes · 0 reposts · 1 replies Open on X →
Last week, we welcomed the US Ambassador to the UK, Warren Stephens, to The Discovery Center, our global headquarters and state-of-the-art R&D facility in Cambridge. https://t.co/lWd3F7hlxr
1.5K views · 2 likes · 0 reposts · 1 replies Open on X →
Today, the FDA has approved a new treatment option for individuals living with hypereosinophilic syndrome (HES), a rare disease driven by elevated eosinophils in the blood, which can lead to progressive organ damage over time. Read more about the approval: https://t.co/yGWxyYURFK
0:11
1.5K views · 3 likes · 0 reposts · 0 replies Open on X →
The FDA just announced the approval of a new way to self-administer therapy for people living with systemic lupus erythematosus (SLE). Learn more: https://t.co/1Ra9EW94yG https://t.co/wfjPziPC35
0:10
823 views · 4 likes · 1 reposts · 1 replies Open on X →

Against accounts of the same size

1 posts from the last 90 days, next to the 10K–100K follower range. below its peers on both reach and engagement.

Median views1 060this account961median for 10K–100K
Reach, %1.32%this account3.53%median for 10K–100K
Engagement, %0.66%this account1.59%median for 10K–100K
MetricThis accountMedian for 10K–100KRatio
Median views per post1 0609611.10×
Reach (views ÷ followers)1.32%3.53%0.37×
Engagement rate0.66%1.59%0.42×

Others in this range →   Compare with another account →   How these benchmarks are built →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

82327 Apr
1.5K14 May
1.5K4 Jun
1.2K
541
3.4K5 Jun
1.1K27 Aug

Last 7 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.73%27 Apr
0.20%14 May
0.20%4 Jun
0.24%
0.37%
0.32%5 Jun
0.66%27 Aug

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.59%.

What the audience does

Likes80.6%29 in total
Reposts8.3%3 in total
Replies8.3%3 in total
Bookmarks2.8%1 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Similar accounts